Compare Cintas Corporation (CTAS) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cintas Corporation vs ResMed Inc. — how do they compare? Cintas Corporation trades at $205.78 (market cap $82.15B), while ResMed Inc. trades at $225 (market cap $32.61B). The key difference: Cintas Corporation is far larger — about 2.5× ResMed Inc.'s market cap, and ResMed Inc. pays the higher dividend (1.17%). Which is the better fit depends on your goals.
| CTAS | RMD | |
|---|---|---|
Market Cap | $82.15B | $32.61B |
Sector | Industrials | Health |
52-Week High | $225.10 | $293.73 |
52-Week Low | $163.55 | $182.82 |
Enterprise Value | $84.56B | $31.97B |
Dividend Yield | 1.01% | 1.17% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cintas (CTAS) trades at $203.51, up 0.39% on the day, with a bullish technical signal and recent earnings beats driving momentum. The company reported strong fiscal 2026 results with revenue of $10.34 billion and net income of $1.81 billion, supported by robust profitability margins. Analyst consensus is a 'Buy' with a $225.83 price target, though valuation multiples like a P/E of 41.81 suggest premium pricing. Recent news highlights dividend declarations and institutional buying interest.
Outlook remains positive given consistent earnings outperformance and upward revenue guidance, but risks include high valuation sensitivity and economic cyclicality. The stock offers growth potential from operational efficiency and market share gains, yet investors should weigh elevated multiples against sector peers.
ResMed (RMD) trades at $226.00, up 2.7% with strong technical momentum and bullish moving averages. The company delivered three consecutive quarterly EPS beats, with Q4 2026 revenue growing 9% to $1.5 billion and non-GAAP EPS rising 16% to $2.95. Fundamentals show robust profitability with 26.94% net margin and 24.27% ROE, though weak 2027 revenue guidance has tempered sentiment.
Outlook remains positive with analyst consensus target of $235 offering 4% upside, but risks include ventilator sales suspension and cost pressures. The stock's current valuation at 21.56 P/E appears reasonable given strong cash flow generation and consistent dividend payments, making it attractive for growth-oriented healthcare investors despite near-term guidance concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cintas Corporation
In its core uniform and facility services unit (78% of sales), Cintas provides uniform rental programs to businesses across the size spectrum, mostly in North America. The firm is by far the largest provider in the industry. Facilities products generally include the rental and sale of entrance mat, mops, shop towels, hand sanitizers, and restroom supplies. Cintas also runs a first aid and safety services business (11% of sales), a fire protection services business (7% of sales), and a uniform direct sales business (4% of sales).
Read more on CTAS →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
